In a matter involving alleged abuse of the U.S. Pharmacopeia standard setting process, CRA examined market power for product dispensed through hospital and non-hospital sites of care. CRA’s expert found that in most uses, during the relevant time period there was ample evidence of competition, finding that the manufacturer at issue was effectively price constrained by existing competition.
A tale of two stakeholder groups in regulating healthcare AI
Despite significant spending on healthcare in the US, the industry is slow to adopt AI technology that can cut costs and improve efficiency. In this CPI...